S&P 500   5,055.61 (+1.48%)
DOW   38,859.21 (+0.64%)
QQQ   436.01 (+2.44%)
AAPL   183.07 (+0.41%)
MSFT   411.94 (+2.43%)
META   486.22 (+3.89%)
GOOGL   144.17 (+1.14%)
AMZN   172.99 (+2.61%)
TSLA   192.65 (-1.09%)
NVDA   778.57 (+15.39%)
NIO   5.73 (-4.02%)
AMD   181.36 (+10.39%)
BABA   75.56 (-0.03%)
T   16.61 (-2.29%)
F   12.19 (+0.41%)
MU   85.60 (+5.04%)
CGC   3.41 (-0.87%)
GE   151.26 (+1.47%)
DIS   108.22 (+0.51%)
AMC   4.51 (-1.31%)
PFE   27.24 (-1.55%)
PYPL   57.76 (+0.49%)
XOM   104.62 (-0.22%)
S&P 500   5,055.61 (+1.48%)
DOW   38,859.21 (+0.64%)
QQQ   436.01 (+2.44%)
AAPL   183.07 (+0.41%)
MSFT   411.94 (+2.43%)
META   486.22 (+3.89%)
GOOGL   144.17 (+1.14%)
AMZN   172.99 (+2.61%)
TSLA   192.65 (-1.09%)
NVDA   778.57 (+15.39%)
NIO   5.73 (-4.02%)
AMD   181.36 (+10.39%)
BABA   75.56 (-0.03%)
T   16.61 (-2.29%)
F   12.19 (+0.41%)
MU   85.60 (+5.04%)
CGC   3.41 (-0.87%)
GE   151.26 (+1.47%)
DIS   108.22 (+0.51%)
AMC   4.51 (-1.31%)
PFE   27.24 (-1.55%)
PYPL   57.76 (+0.49%)
XOM   104.62 (-0.22%)
S&P 500   5,055.61 (+1.48%)
DOW   38,859.21 (+0.64%)
QQQ   436.01 (+2.44%)
AAPL   183.07 (+0.41%)
MSFT   411.94 (+2.43%)
META   486.22 (+3.89%)
GOOGL   144.17 (+1.14%)
AMZN   172.99 (+2.61%)
TSLA   192.65 (-1.09%)
NVDA   778.57 (+15.39%)
NIO   5.73 (-4.02%)
AMD   181.36 (+10.39%)
BABA   75.56 (-0.03%)
T   16.61 (-2.29%)
F   12.19 (+0.41%)
MU   85.60 (+5.04%)
CGC   3.41 (-0.87%)
GE   151.26 (+1.47%)
DIS   108.22 (+0.51%)
AMC   4.51 (-1.31%)
PFE   27.24 (-1.55%)
PYPL   57.76 (+0.49%)
XOM   104.62 (-0.22%)
S&P 500   5,055.61 (+1.48%)
DOW   38,859.21 (+0.64%)
QQQ   436.01 (+2.44%)
AAPL   183.07 (+0.41%)
MSFT   411.94 (+2.43%)
META   486.22 (+3.89%)
GOOGL   144.17 (+1.14%)
AMZN   172.99 (+2.61%)
TSLA   192.65 (-1.09%)
NVDA   778.57 (+15.39%)
NIO   5.73 (-4.02%)
AMD   181.36 (+10.39%)
BABA   75.56 (-0.03%)
T   16.61 (-2.29%)
F   12.19 (+0.41%)
MU   85.60 (+5.04%)
CGC   3.41 (-0.87%)
GE   151.26 (+1.47%)
DIS   108.22 (+0.51%)
AMC   4.51 (-1.31%)
PFE   27.24 (-1.55%)
PYPL   57.76 (+0.49%)
XOM   104.62 (-0.22%)

Daré Bioscience (DARE) Stock Forecast & Price Target

$0.38
+0.02 (+4.20%)
(As of 10:33 AM ET)

Daré Bioscience Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

$6.00
1,491.51% Upside
High Forecast$6.00
Average Forecast$6.00
Low Forecast$6.00
TypeCurrent Forecast
2/22/23 to 2/22/24
1 Month Ago
1/23/23 to 1/23/24
3 Months Ago
11/24/22 to 11/24/23
1 Year Ago
2/22/22 to 2/22/23
Consensus Rating
Moderate Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.00$6.00$6.00$9.33
Predicted Upside1,491.51% Upside1,718.18% Upside1,718.18% Upside755.52% Upside
Get Daré Bioscience Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.


DARE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DARE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Daré Bioscience Stock vs. The Competition

TypeDaré BioscienceMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside1,558.37% Upside1,098.85% Upside8.58% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/30/2024Dawson James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
11/10/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$7.00 ➝ $6.00+1,718.13%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:03 AM ET.












DARE Price Target - Frequently Asked Questions

What is Daré Bioscience's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Daré Bioscience stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for DARE. The average twelve-month price prediction for Daré Bioscience is $6.00 with a high price target of $6.00 and a low price target of $6.00. Learn more on DARE's analyst rating history.

Do Wall Street analysts like Daré Bioscience more than its competitors?

Analysts like Daré Bioscience less than other Medical companies. The consensus rating score for Daré Bioscience is 2.50 while the average consensus rating score for medical companies is 2.68. Learn more on how DARE compares to other companies.

Is Daré Bioscience being downgraded by Wall Street analysts?

Over the previous 90 days, Daré Bioscience's stock had 1 downgrade by analysts.

Does Daré Bioscience's stock price have much upside?

According to analysts, Daré Bioscience's stock has a predicted upside of 1,718.18% based on their 12-month stock forecasts.

What analysts cover Daré Bioscience?

Daré Bioscience has been rated by Dawson James in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DARE) was last updated on 2/22/2024 by MarketBeat.com Staff